Language

VibroSense Dynamics: First order to VibroSense Dynamics in the area of treatment of cancer with Chemotherapy

VibroSense Dynamics (VibroSense) has received a first commercial purchase order targeting Chemotherapy-Induced Peripheral Neuropathy (CIPN). The department of Oncology at Linköping University Hospital has signed a “pay per use” agreement for the VibroSense Meter product.

The department of Oncology at Linköping University Hospital has signed a license agreement with VibroSense Dynamics. The clinic shall test the VibroSense Meter instrument and Multi Frequency Vibrometry for six months. The aim is to investigate the extent of nerve damage in patients treated with Chemotherapy. All patients will be examined with at new quantitative examination method, called Multi Frequency Vibrometry, for assessment of the vibration perception within a frequency range of 4 to 500 Hz. If the test confirms neurological status in the hands of the patients, the clinic intends to conduct a CIPN study and thus extend the license agreement.

- “The order from the department of Oncology at Linköping University Hospital is very promising to VibroSense. I see this as a first acknowledgment of our strategy aiming at introducing our technology to Scientists in oncology and chemotherapy. From an international perspective, Scientists are an important and large customer group and the company will benefit from new research results. Each new study contributes with valuable knowledge to VibroSense and it will also provide support to our marketing and sales", says Toni Speidel, CEO VibroSense Dynamics AB

Contact

Toni Speidel, CEO VibroSense Dynamics AB,

Tel: +46 40 650 14 12

E-mail: info@vibrosense.com

www.vibrosense.com

This information is information that VibroSense Dynamics AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on Mars 19th 2018.

About VibroSense Dynamics AB (publ)

VibroSense Dynamics AB (public) develops and markets efficient systems to aid early detection and diagnosis of sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in e.g. legs and arms. The Company, founded in 2005, has been listed on AktieTorget since May 2015.